NexMed Appoints Dr. Jay Birnbaum to Its Scientific Advisory Board.EAST WINDSOR East Windsor is the name of the following places in the United States of America:
Commenting on today's news, Vivian Liu, Chief Executive Officer, noted, "We are pleased to welcome Jay to our Scientific Advisory Board chaired by Dr. David Tierney. Jay was involved in the development of our anti-fungal product which is now in pivotal Phase 3 trials. As part of our Scientific Advisory Board, we are delighted that Jay will now play an even more active part in the continued development and expansion of our product pipeline." Dr. Birnbaum is currently a consultant focused on ethical and OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). dermatologicals, devices, and cosmeceuticals, serving clients that include large pharmaceutical companies. Prior to establishing his consulting company Noun 1. consulting company - a firm of experts providing professional advice to an organization for a fee consulting firm business firm, firm, house - the members of a business organization that owns or operates one or more establishments; "he worked for a in 1999, Dr. Birnbaum was with Novartis/Sandoz Pharmaceuticals Corporation, serving most recently as Vice President, Global Project Management. In that capacity, Dr. Birnbaum was responsible for oversight and management of the dermatology project/product portfolio, including oral and topical Lamisil([R]) anti-fungal products. Before joining Novartis/Sandoz, Dr. Birnbaum held various management positions at the Medical and Consumer Products Divisions of American Cyanamid American Cyanamid was a large, diversified, American chemical manufacturer. Lederle Laboratories, maker of Centrum and Stresstabs vitamins, was Cyanamid's pharmaceutical division. Davis & Geck was the company's medical device division. Company (Wyeth). Dr. Birnbaum has broad relationships in industry, academia, and professional organizations and has published extensively on his work in drug development. He earned his Ph.D. in Pharmacology from the University of Wisconsin and a B.S. degree in Biology from Trinity College Trinity College, Ireland: see Dublin, Univ. of. Trinity College Private liberal arts college in Hartford, Conn., founded in 1823. It is historically affiliated with the Episcopal church, though its curriculum is nonsectarian. . About NexMed NexMed, Inc. is leveraging its proprietary NexACT[R] drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed's novel, onychomycosis treatment, licensed to Novartis, is currently in pivotal Phase 3 trials in the U.S. and Europe. The Company's topical treatment for erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. is licensed to Warner Chilcott, Ltd., and its New Drug Application was accepted for review by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in November 2007. NexMed's pipeline also includes a Phase 2 treatment for female sexual arousal disorder Female Sexual Arousal Disorder Definition Female sexual arousal disorder (FSAD) occurs when a woman is continually unable to attain or maintain arousal and lubrication during intercourse, is unable to reach orgasm, or has no desire for sexual and an early stage treatment for psoriasis. For further information about the Company, go to www.nexmed.com. Statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and : with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion